Researchers at the University of Michigan have discovered a connection between two immune-regulating proteins that could help overcome resistance to cancer immunotherapy. Their work shows how targeting one of these proteins can enhance the immune response and improve treatment effectiveness across several tumor types. The findings from the Rogel Cancer Center open new possibilities for developing broader cancer therapies.
